Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative Online education and training Order products online Reimbursement resources Return a product Customer support

Call customer care

1 (888) 272-1001

 

Medical Specialties > Interventional Cardiology > Coronary Interventions > PCI Product Portfolio > SYNERGY XD™ Bioabsorbable Polymer Stent

Xtra Deliverability
Optimal Healing
Long Lesions
SYNERGY™ XD
 

The First DES Indicated for Use in High Bleeding Risk Patients

The SYNERGY XD Stent can be safely used in conjunction with shortened DAPT in patients at high risk for bleeding, based on the results from the EVOLVE Short DAPT Trial.*

Now FDA Approved - SYNERGY XD Stent, High Bleeding Risk Indication
 
EVOLVE Short DAPT Trial

EVOLVE Short DAPT Trial†1

Studying 3-month DAPT in high bleeding risk patients†1

See the Latest Data
EVOLVE Short DAPT Trial

0.2% ST

from 3-15 months

 
 

Designed for Early Healing

Trusted Everolimus Drug + Bioabsorbable Polymer

Trusted Everolimus Drug + Bioabsorbable Polymer

Unlike permanent polymer DES technology, the SYNERGY XD Bioabsorbable Polymer is gone shortly after the drug is completely eluted2

Trusted Everolimus Drug + Bioabsorbable Polymer
 
 

Leading on Studying Short DAPT

SENIOR Trial

SENIOR Trial

Studying 1-month DAPT in elderly patients‡§3

Get the Latest Data
Low Crossing Profile

0% ST

from 1-12 months**

 
ASET Trial

ASET Trial

Studying 0-month DAPT in patients with chronic stable anginaࠠ4

Get More Info
0% ST at 3-months

0% ST

at 3-months

 
 

Excellent Safety & Long Term Outcomes

Kang Network Meta-Analysis

Kang Network Meta-Analysis

SYNERGY BP Stent ranked #1 for the lowest relative risk of def/prob ST at 1-year. §5

See the Data
Ranked #1 lowest relative risk of def/prob ST

Ranked #1

Lowest relative risk of Def/Prob ST

 
Real-World SCAAR Registry

Real-World SCAAR Registry

Lowest ST rate compared to newer generation DES despite use in patients with statistically more Class B2/C lesions, diabetes, prior PCI, and 3VD.*,**,6

Learn More
Real-World SCAAR Registry

Excellent Results in

Complex Patients

Lowest ST rate in statistically more complex patients

 
 
 

Get More Info

Get more in depth and learn more about product specifications and ordering information.
  Learn More  

Talk to a Rep

Fill out a quick form and one of our sales representatives will be in touch. 
  Let's Talk  
Top